Back to Search Start Over

What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.

What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases.

Authors :
Evans JF
Ferguson AD
Mosley RT
Hutchinson JH
Source :
Trends in pharmacological sciences [Trends Pharmacol Sci] 2008 Feb; Vol. 29 (2), pp. 72-8. Date of Electronic Publication: 2008 Jan 09.
Publication Year :
2008

Abstract

Leukotrienes have physiological roles in innate immune responses and pathological roles in inflammatory diseases, such as asthma, allergic rhinitis and atherosclerosis. Anti-leukotriene therapy has proven benefits in the treatment of respiratory disease, either through the inhibition of leukotriene synthesis or the selective antagonism of leukotriene receptors. The first committed step in the synthesis of leukotrienes is the oxidation of arachidonic acid (AA) by 5-lipoxygenase (5-LO), and the integral membrane protein 5-lipoxygenase-activating protein (FLAP) is an essential partner of 5-LO for this process. FLAP was molecularly identified via a photoaffinity probe and an affinity gel based on MK-886, a selective leukotriene inhibitor that has no activity against broken-cell preparations of 5-LO. Several FLAP inhibitors showed efficacy in early clinical trials in asthma but were not developed commercially for unpublished reasons. Recently, the FLAP (ALOX5AP) gene has been linked to risk for myocardial infarction, stroke and restenosis, reigniting pharmaceutical interest in this target. In addition, the recent determination of the crystal structure of inhibitor-bound FLAP offers exciting potential for novel FLAP inhibitor design.

Details

Language :
English
ISSN :
0165-6147
Volume :
29
Issue :
2
Database :
MEDLINE
Journal :
Trends in pharmacological sciences
Publication Type :
Academic Journal
Accession number :
18187210
Full Text :
https://doi.org/10.1016/j.tips.2007.11.006